Watertown, MA, United States of America

Sepehr Kiani

This inventor holds 57 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 8 EPO patents, primarily in Microfluidic Devices (CPC class B01L). Top assignees: Bio-Rad Laboratories, Inc., Teradyne, Inc., Amphenol Corporation. Active years: 1999-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sepehr Kiani. Retrieved from https://idiyas.com/inventor/sepehr-kiani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 57 

% Patents Active = 57.9

 

 

Average Co-Inventor Count = 2.4

ph-index = 15

Forward Citations = 937(Granted Patents)

Forward Citations (Not Self Cited) = 861(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Cambridge, MA (US) (2016 - 2020)
  • Watertown, MA (US) (1999 - 2024)

Company Filing History:


Years Active: 1999-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Single Cell Sequencing
Viral Detection
Multi-Omic Analysis
Microfluidic Devices
Droplet Inflation
Drug Screening
Spectroscopic Intensity
Optical Connectors
Droplet Velocity
Liquid Reagents
Ferrule Assembly
Modular Connector Systems
57 patents (USPTO):Explore Patents

Title: **Sepehr Kiani: Innovator in Single-Cell Analysis**

Introduction

Sepehr Kiani, based in Watertown, MA, is a prominent inventor and researcher known for his significant contributions to the field of biotechnology. With an impressive portfolio of 53 patents, Kiani has played a crucial role in advancing methods for single-cell analysis, particularly in the context of genomics and proteomics.

Latest Patents

Among his latest innovations, Kiani has developed patented methods and systems for "Multi-omic analysis in monodisperse droplets." This groundbreaking technology allows for single-cell, multi-omic analysis of target cells without relying on microfluidic devices. By using template particles to create monodisperse droplets, his system captures a single target cell from a population and enables the extraction and quantification of distinct mRNA molecules, generating an expression profile. Additionally, he has designed nucleic-acid-tagged antibody conjugates that facilitate simultaneous proteomic analysis alongside gene expression profiling.

Another remarkable patent involves "Methods and systems for single cell gene profiling." This invention further enhances single-cell analysis, specifically transcriptome analysis, by utilizing similar techniques to encapsulate and analyze target cells without the need for microfluidic apparatus.

Career Highlights

Kiani has been affiliated with several esteemed companies throughout his career, including Bio-Rad Laboratories, Inc. and Teradyne, Inc. His work in these organizations has significantly contributed to the development of tools and methodologies that enhance research capabilities in genomic and proteomic studies.

Collaborations

Throughout his career, Kiani has collaborated with talented individuals, including his coworkers Tony Hung and Richard F. Roth. These collaborations have likely fostered an environment of innovation, resulting in the creation of cutting-edge technologies that push the boundaries of current scientific understanding.

Conclusion

Sepehr Kiani's dedication to innovation in single-cell analysis showcases his importance in the biotechnology field. With a substantial number of patents highlighting his groundbreaking work, Kiani continues to influence the advancement of methodologies that are essential for ongoing research in molecular biology and personalized medicine. His contributions are paving the way for future discoveries that promise to improve healthcare outcomes and scientific knowledge.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…